Version 3 of the Alzheimer Disease Centers’ Neuropsychological Test Battery in the Uniform Data Set (UDS)

Introduction: The neuropsychological battery of the Uniform Data Set (UDSNB) was implemented in 2005 by the National Institute on Aging (NIA) Alzheimer Disease Centers program to measure cognitive performance in dementia and mild cognitive impairment due to Alzheimer Disease. This paper describes a revision, the UDSNB 3.0. Methods: The Neuropsychology Work Group of the NIA Clinical Task Force recommended revisions through a process of due diligence to address shortcomings of the original battery. The UDSNB 3.0 covers episodic memory, processing speed, executive function, language, and constructional ability. Data from 3602 cognitively normal participants in the National Alzheimer Coordinating Center database were analyzed. Results: Descriptive statistics are presented. Multivariable linear regression analyses demonstrated score differences by age, sex, and education and were also used to create a normative calculator available online. Discussion: The UDSNB 3.0 neuropsychological battery provides a valuable non proprietary resource for conducting research on cognitive aging and dementia.

[1]  C. Luis,et al.  Cross validation of the Montreal Cognitive Assessment in community dwelling older adults residing in the Southeastern US , 2009, International journal of geriatric psychiatry.

[2]  Marcella Laiacona,et al.  Montreal Cognitive Assessment (MoCA)-Italian version: regression based norms and equivalent scores , 2015, Neurological Sciences.

[3]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[4]  Andrew J. Saykin,et al.  Alterations in brain structure and function in breast cancer survivors: effect of post-chemotherapy interval and relation to oxidative DNA damage , 2012, Breast Cancer Research and Treatment.

[5]  D. Salmon,et al.  Clinical and Neuropathological Findings in Lewy Body Dementias , 1996, Brain and Cognition.

[6]  J. Morris,et al.  The Uniform Data Set (UDS): Clinical and Cognitive Variables and Descriptive Data From Alzheimer Disease Centers , 2006, Alzheimer disease and associated disorders.

[7]  Brent A. Vogt,et al.  Atypical form of Alzheimer's disease with prominent posterior cortical atrophy: A review of lesion distribution and circuit disconnection in cortical visual pathways , 1997, Vision Research.

[8]  R. Martins,et al.  Insulin Effects on Glucose Metabolism, Memory, and Plasma Amyloid Precursor Protein in Alzheimer's Disease Differ According to Apolipoprotein‐E Genotype , 2000, Annals of the New York Academy of Sciences.

[9]  D. Salmon,et al.  The Multilingual Naming Test in Alzheimer's Disease: Clues to the Origin of Naming Impairments , 2013, Journal of the International Neuropsychological Society.

[10]  Bruce L. Miller,et al.  Distinct neuroanatomical substrates and cognitive mechanisms of figure copy performance in Alzheimer's disease and behavioral variant frontotemporal dementia , 2011, Neuropsychologia.

[11]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[12]  K. Possin,et al.  Visual spatial cognition in neurodegenerative disease , 2010, Neurocase.

[13]  Nathaniel Mercaldo,et al.  The Alzheimer's Disease Centers' Uniform Data Set (UDS): The Neuropsychologic Test Battery , 2009, Alzheimer disease and associated disorders.

[14]  J. Miller,et al.  Relationship between the Activities of Daily Living Questionnaire and the Montreal Cognitive Assessment , 2016, Alzheimer's & dementia.

[15]  David R. Roalf,et al.  Comparative accuracies of two common screening instruments for classification of Alzheimer's disease, mild cognitive impairment, and healthy aging , 2013, Alzheimer's & Dementia.

[16]  Lilah M. Besser,et al.  Results From the NACC Uniform Data Set Neuropsychological Battery Crosswalk Study , 2016, Alzheimer disease and associated disorders.

[17]  T. Gollan,et al.  Self-ratings of spoken language dominance: A Multilingual Naming Test (MINT) and preliminary norms for young and aging Spanish–English bilinguals* , 2011, Bilingualism: Language and Cognition.

[18]  Meghan B. Mitchell,et al.  A web-based normative calculator for the uniform data set (UDS) neuropsychological test battery , 2011, Alzheimer's Research & Therapy.

[19]  Andrew J. Saykin,et al.  Relationship between the Montreal Cognitive Assessment and Mini-mental State Examination for assessment of mild cognitive impairment in older adults , 2015, BMC Geriatrics.

[20]  H. Chertkow,et al.  Montreal Cognitive Assessment Memory Index Score (MoCA‐MIS) as a Predictor of Conversion from Mild Cognitive Impairment to Alzheimer's Disease , 2014, Journal of the American Geriatrics Society.

[21]  A. Saykin,et al.  Cognitive‐behavioral management of chemotherapy‐related cognitive change , 2007, Psycho-oncology.

[22]  H. Chertkow,et al.  Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample , 2012, Neurology.

[23]  A. Saykin,et al.  Chemotherapy-induced amenorrhea: a prospective study of brain activation changes and neurocognitive correlates , 2013, Brain Imaging and Behavior.

[24]  A. Saykin,et al.  Methylphenidate and Memory and Attention Adaptation Training for Persistent Cognitive Symptoms after Traumatic Brain Injury: A Randomized, Placebo-Controlled Trial , 2017, Neuropsychopharmacology.

[25]  F. Goldstein,et al.  Validity of the Montreal Cognitive Assessment as a Screen for Mild Cognitive Impairment and Dementia in African Americans , 2014, Journal of geriatric psychiatry and neurology.

[26]  C. Derouesné.  [Mini-mental state examination]. , 2001, Revue neurologique.

[27]  Y. Sheline,et al.  Memory improvement following induced hyperinsulinemia in alzheimer's disease , 1996, Neurobiology of Aging.

[28]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[29]  D. Stuss,et al.  Criterion and Convergent Validity of the Montreal Cognitive Assessment with Screening and Standardized Neuropsychological Testing , 2013, Journal of the American Geriatrics Society.

[30]  K Patterson,et al.  Focal cortical presentations of Alzheimer's disease. , 2007, Brain : a journal of neurology.

[31]  Joylee Wu,et al.  The National Alzheimer's Coordinating Center (NACC) Database: The Uniform Data Set , 2007, Alzheimer disease and associated disorders.

[32]  Woodrow D. Deitrich,et al.  The National Alzheimer's Coordinating Center (NACC) Database: An Alzheimer Disease Database , 2004, Alzheimer disease and associated disorders.

[33]  K. Perryman,et al.  Posterior Cortical Atrophy: Clinical Characteristics and Differences Compared to Alzheimer’s Disease , 2002, Dementia and Geriatric Cognitive Disorders.

[34]  A. Larner.  Screening utility of the Montreal Cognitive Assessment (MoCA): in place of – or as well as – the MMSE? , 2011, International Psychogeriatrics.

[35]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[36]  Douglas Galasko,et al.  Neuropsychological Deficits Associated with Diffuse Lewy Body Disease , 1996, Brain and Cognition.

[37]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[38]  S. Weintraub,et al.  The Activities of Daily Living Questionnaire: A Validation Study in Patients with Dementia , 2004, Alzheimer disease and associated disorders.

[39]  S. Hemrungrojn,et al.  The Montreal Cognitive Assessment—Basic: A Screening Tool for Mild Cognitive Impairment in Illiterate and Low‐Educated Elderly Adults , 2015, Journal of the American Geriatrics Society.